CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, a clinical-stage biopharmaceutical company, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. The management team will present on March 16, 2022, at 10 am EST. CinCor focuses on developing CIN-107, an oral small molecule inhibitor of aldosterone synthase, to treat hypertension and cardio-renal diseases. Investors can contact Oppenheimer & Co. for meeting arrangements during the conference.
- None.
- None.
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team will present at the 32nd Annual Oppenheimer Healthcare Conference taking place March 15-17, 2022.
| Event: | 32nd Annual Oppenheimer Healthcare Conference |
| Presentation: | Wednesday, March 16, 2022 at 10 am EST |
Management will also meet with investors during the event. Investors interested in meeting with the CinCor management team during the conference should contact their Oppenheimer & Co. representative.
About CinCor
CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.
Contacts:
Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO
Investors:
Bob Yedid
LifeSci Advisors
ir@CinCor.com
FAQ
When will CinCor Pharma present at the Oppenheimer Healthcare Conference?
What is the focus of CinCor Pharma's clinical candidate CIN-107?
Where is the Oppenheimer Healthcare Conference taking place?
How can investors meet with CinCor management at the conference?
